For Media

Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.

7966727963517945727944317939927923537916777878157847397842625adaf646-c8e9-4688-8400-324bb93b1c5058393312-8ab6-4db5-8faa-d7886a5da19f4b3cce63-1ec7-46eb-9496-a1a94a8ec60b90024061-2609-4dc4-ac8f-91090f02dd0f05644055-047e-41ae-b5eb-ed9854e4ae8f9f47c69b-0cf4-45a4-bdad-b9750ad7b76becc4e99e-66f9-4aa3-abbe-10f1e20ec00022e76c18-6eb6-4e55-956b-487ddb1164af361e4ade-fa3d-4ef5-892e-7dea2be77c75fabe6946-f091-4f9d-850b-83d92f310bb7ARGS_News_2014_11_25_General_Releases.pdfARGS_News_2014_11_24_General_Releases.pdfARGS_News_2014_11_13_General_Releases.pdfARGS_News_2014_11_13_General_Releases.pdfARGS_News_2014_11_12_General_Releases.pdfARGS_News_2014_11_6_General_Releases.pdfARGS_News_2014_11_5_General_Releases.pdfARGS_News_2014_10_22_General_Releases.pdfARGS_News_2014_10_3_General_Releases.pdfARGS_News_2014_10_1_General_Releases.pdf18077246153345419466179841790313226977942278017978123456789102014-11-25T9:35:0-5:02014-11-24T8:30:0-5:02014-11-13T16:5:0-5:02014-11-13T8:30:0-5:02014-11-12T8:30:0-5:02014-11-6T8:30:0-5:02014-11-5T0:0:0-5:02014-10-22T10:0:0-5:02014-10-3T11:0:0-5:02014-10-1T8:30:0-5:0884863884537882950882799882427881092880681877543874493873990General ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesRed Herring Editorial Team Highlights the Argos Arcelis(R) Technology Platform for Developing Fully Personalized Immunotherapies as Important Advance in the Life Science Market.Conference Call and Webcast Today, November 13th, at 4:30 p.m. ETInvetech to supply automated production systems for commercialization of patient-specific immunotherapies based on Argos’ proprietary Arcelis® technology platform.Argos Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare ConferenceArgos Therapeutics Receives 2014 Red Herring North America Top 100 AwardArgos Therapeutics Reports Third Quarter 2014 Financial Results and Operational HighlightsPhilippe Van Holle Joins Argos Therapeutics Board of DirectorsArgos Therapeutics to Present at the Stifel 2014 Healthcare ConferenceArgos Therapeutics to Hold Third Quarter 2014 Financial Results Conference Call on Thursday, November 13, 2014Invetech and Argos Therapeutics Announce Agreement to Support Global Production of Fully Personalized Immunotherapies Argos Therapeutics Breaks Ground on State-of-the-Art Biomanufacturing Facility in Research Triangle Park AreaArgos Therapeutics Announces Plans for New Manufacturing Facility in Research Triangle Park Area in Durham, North CarolinaArgos Therapeutics to Present at the 13th Annual BIO Investor Forum757575757575757575752014201420142014201420142014201420142014No Error0

Argos Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
Read more

Argos Therapeutics Receives 2014 Red Herring North America Top 100 Award
Read more

Argos Therapeutics Reports Third Quarter 2014 Financial Results and Operational Highlights
Read more

Philippe Van Holle Joins Argos Therapeutics Board of Directors
Read more

Argos Therapeutics to Present at the Stifel 2014 Healthcare Conference
Read more

Argos Therapeutics to Hold Third Quarter 2014 Financial Results Conference Call on Thursday, November 13, 2014
Read more

Invetech and Argos Therapeutics Announce Agreement to Support Global Production of Fully Personalized Immunotherapies
Read more

Argos Therapeutics Breaks Ground on State-of-the-Art Biomanufacturing Facility in Research Triangle Park Area
Read more

Argos Therapeutics Announces Plans for New Manufacturing Facility in Research Triangle Park Area in Durham, North Carolina
Read more

Argos Therapeutics to Present at the 13th Annual BIO Investor Forum
Read more